1. Scrip
  2. >>Focus On Asia
  3. >>China

More Uncertainty For Biopharma Players As China Economic Growth Falters

30% Of EU Businesses Report Revenue Decline

 
• By Brian Yang

China's faltering macro economic steam indicates a slowdown in consumption and a lack of new growth engines, adding further woes to an already challenging environment for international players in the biopharma sector.

China NDA in 2021 sized 1200
China's faltering economy adds new uncertainty for foreign health sector players • Source: Shutterstock

China could prove to be a drag instead of a driver for biopharma companies looking to benefit from the country’s post-pandemic rebound. 

The latest figures from the National Statistics Bureau released on 17 July indicate growth in the overall Chinese economy in the first two quarters was relatively anemic, at 5.5%. In the second quarter it was 6

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia